Imexpharm Corporation Sustainability Profile
Imexpharm Corporation, a leading pharmaceutical company based in Vietnam, has been a key player in the industry since its establishment in 2003. With its headquarters in Ho Chi Minh City, the company operates extensively across Southeast Asia, focusing on the development, manufacturing, and distribution of high-quality generic medicines and healthcare products. Imexpharm is renowned for its diverse portfolio, which includes a wide range of pharmaceuticals, from antibiotics to cardiovascular medications. The company prides itself on its commitment to quality and innovation, utilising advanced technology and stringent quality control measures to ensure the efficacy and safety of its products. Recognised for its significant contributions to the healthcare sector, Imexpharm has achieved notable milestones, including various certifications and partnerships that enhance its market position. With a strong emphasis on research and development, Imexpharm continues to expand its reach and impact in the pharmaceutical landscape.
DitchCarbon Score
How does Imexpharm Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Imexpharm Corporation's score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Imexpharm Corporation's reported carbon emissions
Imexpharm Corporation, headquartered in Vietnam, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Imexpharm Corporation has not inherited any emissions data from a parent or related organization, nor does it participate in any recognised climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific commitments or data, it is unclear how Imexpharm Corporation aligns with these industry trends.
How Carbon Intensive is Imexpharm Corporation's Industry?
How Carbon Intensive is Imexpharm Corporation's Location?
Imexpharm Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Imexpharm Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
